Affluent Medical Appoints New Leaders to Advance Medical Innovations

Affluent Medical, a French clinical-stage medical technology company, has announced key leadership appointments to enhance its Medical and Clinical Affairs. Dr. Howard C. Herrmann has been appointed as Chief Medical Officer for the Structural Heart Platform. His extensive experience in interventional cardiology aims to guide the development of next-generation heart devices. Professor Nicolas Barry Delongchamps joins as Chief Medical Officer for the Urology Platform, focusing on innovations in treating urinary issues.

Furthermore, Federica Azzimonti has been named Director of Clinical Operations. With 25 years in managing international clinical studies, her role will be crucial in optimizing clinical trials. These appointments reflect Affluent Medical's strategy to accelerate market access for its advanced products like the KALIOSTM mitral ring, EPYGON mitral valve, and ARTUS urinary sphincter. These devices aim to address significant health issues such as structural heart diseases and urinary incontinence more effectively.